Compound Chamomile and Lidocaine Hydrochloride Gel in Oral Diseases: A Review of Current Evidence and Potential Applications.

Oral diseases frequently entail microbial infections or mucosal damage, typically accompanied by pain and discomfort. Present pharmaceutical interventions for oral conditions in clinical settings are constrained by their singular therapeutic effects, insufficient pain relief, and practical inconveniences. The exploration of novel compound medications holds promise for augmenting clinical treatment outcomes. Compound chamomile and lidocaine hydrochloride gel (CCLHG) represents a composite formulation endowed with analgesic, anti-inflammatory, and wound healing properties, showcasing auspicious potential in oral disease management. This article summarizes the articles of CCLHG in treating various oral diseases. Electronic databases PubMed, Embase, Web of Science, Cochrane Library, Wangfang, China National Knowledge Infrastructure and China Science and Technology Journal Database were searched from inception to August 30, 2025. A total of 1413 articles were searched. 27 articles were finally included. Our analysis reveals preliminary therapeutic potential of CCLHG in managing periodontal diseases, oral mucosal conditions, pericoronitis, dry socket syndrome, peri-implantitis, and related maladies. However, given the overall limited sample sizes, variability in methodology, and generally moderate-to-low quality of the included studies, these findings warrant caution. Further high-quality investigations are therefore essential to substantiate its clinical utility.